Tyr978
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr978  -  EGFR (human)

Site Information
MARDPQRyLVIQGDE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 457580
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 )
Disease tissue studied:
lung cancer ( 1 , 4 ) , non-small cell lung cancer ( 2 , 4 ) , non-small cell lung adenocarcinoma ( 1 , 4 ) , non-small cell squamous cell lung carcinoma ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 5 ) , HCC15 (pulmonary) ( 1 ) , HCC827 (pulmonary) ( 4 ) , HepG2 (hepatic) ( 6 ) , HN5 (squamous) ( 7 ) , LOU-NH91 (squamous) ( 1 ) , lung ( 1 ) , NCI-H1703 (squamous) ( 1 ) , NCI-H2073 (pulmonary) ( 1 ) , NCI-H2342 (pulmonary) ( 1 ) , NCI-H3255 (pulmonary) ( 2 )

Upstream Regulation
Treatments:
EGF ( 5 )

Downstream Regulation
Effects of modification on EGFR:
molecular association, regulation ( 8 )
Induce interaction with:
SHP-2 (human) ( 8 ) , STAT5A (human) ( 8 )

References 

1

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

2

Rikova K (2012) CST Curation Set: 16138; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

3

Possemato A (2012) CST Curation Set: 13559; Year: 2012; Biosample/Treatment: cell line, mixTMT(A549,H3255,MKN45,H3122,,H1703,H1650)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

4

Zhang G, et al. (2011) Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res 10, 305-19
21080693   Curated Info

5

Tong J, et al. (2008) Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor. J Proteome Res 7, 1067-77
18271526   Curated Info

6

Gevaert K, et al. (2005) Global phosphoproteome analysis on human HepG2 hepatocytes using reversed-phase diagonal LC. Proteomics 5, 3589-99
16097034   Curated Info

7

Thelemann A, et al. (2005) Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 4, 356-76
15657067   Curated Info

8

Schulze WX, Deng L, Mann M (2005) Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1, 2005.0008
16729043   Curated Info